Kaplan M J, Somers R G, Greenberg R H, Ackler J
Department of Surgery, Albert Einstein Medical Center, Philadelphia, Pennsylvania 19141, USA.
J Surg Oncol. 1998 Feb;67(2):121-5. doi: 10.1002/(sici)1096-9098(199802)67:2<121::aid-jso9>3.0.co;2-c.
Photodynamic therapy (PDT) using a photoreactive purpurin, tin ethyl etiopurpurin (SnET2, Purlytin, Miravant Medical Technologies, Santa Barbara, CA), was investigated as a treatment for cutaneous metastatic disease that had failed other treatment options.
STUDY DESIGN/MATERIALS AND METHODS: Three patients with biopsy-proven metastatic adenocarcinoma of the skin were treated with a single dose of the study drug. Twenty-four hours later, the patients were exposed to a laser light at 664 nm in multiple light fields. Patients were followed for 6 months for safety, efficacy, recurrence, and palliative response.
After PDT with SnET2, complete response was observed in all 13 treated lesions in three patients, with no evidence of recurrence at any treated site at the 6-month follow-up. Two patients subsequently died of distant metastatic disease. One patient with local chest wall recurrence after mastectomy was disease-free 24 months after PDT.
PDT with SnET2 could be an effective treatment in locally advanced metastatic carcinoma of the skin.
研究使用光反应性紫红素——二乙锡卟吩（SnET2，Purlytin，Miravant医疗技术公司，加利福尼亚州圣巴巴拉）进行光动力疗法（PDT），作为治疗已对其他治疗方案无效的皮肤转移性疾病的一种方法。
研究设计/材料与方法：3例经活检证实为皮肤转移性腺癌的患者接受了单剂量的研究药物治疗。24小时后，患者在多个光场中接受664nm的激光照射。对患者进行了6个月的随访，观察安全性、疗效、复发情况及姑息反应。
使用SnET2进行光动力治疗后，3例患者的13个治疗病灶均观察到完全缓解，在6个月的随访中，任何治疗部位均无复发迹象。2例患者随后死于远处转移性疾病。1例乳房切除术后局部胸壁复发的患者在光动力治疗后24个月无疾病。
使用SnET2进行光动力治疗可能是局部晚期皮肤转移性癌的一种有效治疗方法。
